financetom
Business
financetom
/
Business
/
NameSilo Technologies Down 6% As Q4 Net Loss Widens, Despite Higher Revenues
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
NameSilo Technologies Down 6% As Q4 Net Loss Widens, Despite Higher Revenues
May 25, 2025 11:43 PM

03:03 PM EDT, 05/01/2025 (MT Newswires) -- NameSilo Technologies ( URLOF ) , a domain registrar, was at last look down 6% from shy of 52 week highs as net loss widened in the fourth quarter, despite higher revenues, while the company said it is ready to "deploy our robust cash flow into strategic investments....that will drive the next phase of our growth".

For Q4, net loss was $1.623 million for basic and diluted loss per share of $0.02, wider than a net loss of near $192,000 or $0.00 a year earlier.

The company showed a net income of $304,878 in 2024 compared to a net loss of $1.28 million in 2023, with an adjusted EBITDA of $2.88 million for 2024, up 16%, as compared to $2.48 million in 2023.

It had record revenues of $14,904,237 for Q4 2024 as compared to $12,590,417 in Q4 2023, an increase of 18.4%. The increase in revenues for Q4 2024 was due to an increase in domains under management, marketplace revenues, and from the sale of ancillary services.

Among other highlights, the company had total bookings of $16,919,028 in Q4 2024 compared to $11,851,825 in Q4 2023, and operating cash flow of $2,988,046 in Q4 2024 versus $1,049,543 in Q4 2023.

"2024 marked a pivotal year in our company's journey," said CEO Paul Andreola. "We achieved record-breaking results across revenue, gross profit, and operating profit, reflecting the strength and resilience of our business model. Our substantial growth in free cash flow has enabled us to reduce debt to near-zero levels and build a strong, expanding net cash position. Crossing the milestone of 5 million domains under management has firmly established us among the top-tier domain registrars in the industry. As we look ahead, we're excited to deploy our robust cash flow into strategic investments, including continuing to buy back Namesilo ( URLOF ) shares as appropriate, that will drive the next phase of our growth."

Price: 0.94, Change: -0.06, Percent Change: -6.00

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BranchOut Food Closes $1.4 Million Public Offering
BranchOut Food Closes $1.4 Million Public Offering
Jun 28, 2024
12:18 PM EDT, 06/28/2024 (MT Newswires) -- BranchOut Food ( BOF ) said Friday it has closed its underwritten public offering of 1.75 million common shares at $0.80 apiece for gross proceeds of about $1.4 million. The underwriters have a 45-day option to buy up to 262,500 additional shares at the public offering price, minus underwriting discounts, the company said....
Walgreens' Q3 Earnings Miss Reflects Weak Consumer Spending, Pharmacy Headwinds, Morgan Stanley Says
Walgreens' Q3 Earnings Miss Reflects Weak Consumer Spending, Pharmacy Headwinds, Morgan Stanley Says
Jun 28, 2024
12:25 PM EDT, 06/28/2024 (MT Newswires) -- Walgreens Boots Alliance's ( WBA ) lower-than-expected Q3 earnings stemmed from a weak consumer environment and challenges in the pharmacy industry, Morgan Stanley said in a note Friday. The company reported Q3 adjusted earnings Thursday of $0.63 per diluted share, missing Morgan Stanley's estimate and consensus of $0.69 and $0.71, respectively, according to...
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial
Jun 28, 2024
12:28 PM EDT, 06/28/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday results from a phase 3 study of nipocalimab in generalized myasthenia gravis were positive. Patients treated with nipocalimab plus standard of care achieved superiority over placebo plus SOC as measured by the primary endpoint of improvement in the Myasthenia Gravis- Activities of Daily Living score...
Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies
Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies
Jun 28, 2024
12:29 PM EDT, 06/28/2024 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Friday it secured $3.4 million in nondilutive funding to support its phase 2 trial of intranasal foralumab in nonactive secondary progressive multiple sclerosis and advance research in Alzheimer's disease. We continue to explore all avenues to pursue further nondilutive funding in the near term, acting Chief...
Copyright 2023-2026 - www.financetom.com All Rights Reserved